Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982568priorityCriticalpatent/ECSP982568A/en
Publication of ECSP982568ApublicationCriticalpatent/ECSP982568A/en
Se describen derivados de quinolina y benzazepina que inhibe la farnesil-proteína transferasa (ftasa) y la farnesilación de la proteína oncogénica Ras. De esta manera los compuestos son útiles como agentes anticáncer. Los compuestos también son útiles en el tratamiento de enfermedades diferentes del cáncer.Quinoline and benzazepine derivatives that inhibit farnesyl protein transferase (phthase) and farnesylation of the oncogenic protein Ras are described. In this way the compounds are useful as anticancer agents. The compounds are also useful in the treatment of diseases other than cancer.
ECSP9825681998-06-301998-06-30
FARNESIL PROTEIN TRANSFERASE INHIBITORS
ECSP982568A
(en)